Video Length: 00:36:10
We sat down with Joel Fruendt, CEO of SenesTech (SNES), to dive into their game-changing fertility control solution for rats — and the massive opportunity unfolding across the U.S. and internationally.
Key Topics Covered:
Active pilot deployments in New York City, Los Angeles, Chicago, Boston, San Francisco, Baltimore
Global expansion into Indonesia, India, Netherlands and future EU plans
How SNES could scale from ~$500K/quarter to multi-million-dollar contracts
Timeline for profitability, pilot expansions, and key upcoming catalysts
Inside their new production facility in Arizona with scalable capacity
Why one big citywide contract could flip SNES to profitability — and potentially send the stock soaring
Joel also discusses revenue run-rate targets, the inflection point ahead, and how their proprietary Evolve product is seeing widespread adoption from cities banning poisons.
Watch until the end for investor Q&A on timelines, red tape, and the likelihood of full-city rollouts by year-end.
If you're a microcap investor looking for the next big inflection, this is an interview you don't want to miss.
Related Articles:
SenesTech Remains Undervalued With Increasing Revenues And Global Product Distribution
SenesTech's Big Play On Small Pests
SenesTech: A Little-Known Biotech Company Worthy Of Attention
More By This Author:
SenesTech CEO Reveals Surprise San Francisco Expansion
SenesTech CEO Interview: Breaking Down Record Earnings & The Road To Profitability
Stock Market Outlook: Key Levels, Short Squeeze Plays And Trade Setups
Comments
Log in or sign up to join the conversation.